Comments
Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) for Erythromycin Tablets USP, available in strengths of 250 mg and 500 mg (USRLD: Erythromycin Tablets USP, 250 mg and 500 mg).
Erythromycin Tablets USP, an antibacterial medication, serve to prevent and treat a wide range of infections affecting various parts of the body, including respiratory tract infections, skin infections, diphtheria, intestinal amebiasis, acute pelvic inflammatory disease, Legionnaire’s disease, and pertussis. This drug will be manufactured at the group’s formulation manufacturing facility in the Special Economic Zone (SEZ) in Ahmedabad, India.
However, the shares were down by 1.86 per cent to ₹613 at 01.40 pm on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.